Drugging RNA

With a tranched $38 million series A round led by Canaan Partners, Arrakis Therapeutics Inc. is putting an initial set of hits into preclinical development, and building out a platform that will allow it to systematically screen for small molecules that bind RNA targets, a class long considered to be undruggable.

New investors Pfizer Inc. (NYSE:PFE), Celgene Corp. (NASDAQ:CELG) and Osage University Partners also joined the round, along with seed investors Advent Life Sciences and Henri Termeer...